Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era

To study the main clinico-biological characteristics and the outcome of patients with diffuse large B-cell lymphoma (DLBCL) according to the primary site (nodal vs. extranodal), we included 262 patients consecutively diagnosed with DLBCL in a single institution, 5 years before and after immunochemot...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia & lymphoma 2010-07, Vol.51 (7), p.1225-1232
Main Authors: Gutiérrez-García, Gonzalo, Colomo, Lluis, Villamor, Neus, Arenillas, Leonor, Martínez, Antonio, Cardesa, Teresa, García-Herrera, Adriana, Setoain, Xavier, Rodríguez, Sonia, Ghita, Gabriela, Abrisqueta, Pau, Giné, Eva, Bosch, Francesc, Campo, Elías, Montserrat, Emilio, López-Guillermo, Armando
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cyclophosphamide - administration & dosage
Diffuse large B-cell lymphoma
Doxorubicin - administration & dosage
extranodal
Female
Gastrointestinal Neoplasms - drug therapy
Gastrointestinal Neoplasms - pathology
Humans
immunochemotherapy
immunophenotyping profile
L-Lactate Dehydrogenase - blood
Lymph Nodes - drug effects
Lymph Nodes - pathology
Lymphoma, Large B-Cell, Diffuse - drug therapy
Lymphoma, Large B-Cell, Diffuse - pathology
Male
Middle Aged
Neoplasm Staging
Prednisone - administration & dosage
prognosis
Rituximab
Survival Rate
Treatment Outcome
Vincristine - administration & dosage
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To study the main clinico-biological characteristics and the outcome of patients with diffuse large B-cell lymphoma (DLBCL) according to the primary site (nodal vs. extranodal), we included 262 patients consecutively diagnosed with DLBCL in a single institution, 5 years before and after immunochemotherapy was considered as the standard treatment. Altogether 116 patients received CHOP (cyclophosphamide, adriamycin, vincristine, and prednisone) and 146 rituximab plus CHOP (R-CHOP). The primary site was the lymph node in 140 patients (53%), Waldeyer's ring (WR) in 22, gastrointestinal (GI) in 33, and other extranodal in 67. The addition of rituximab significantly improved the CR rate in nodal, but not in extranodal, lymphomas. Patients receiving R-CHOP showed higher OS than those treated with CHOP alone (5-year OS: 71% vs. 48%). This difference was maintained in primary nodal (5-year OS: 69% vs. 37%, p 
ISSN:1042-8194
1029-2403
DOI:10.3109/10428194.2010.483301